Publikationer 2006-2013, Johan Rönnelid


  1. Klareskog L, Stolt P, Lundberg K, Källberg H, Silva C, Grunevald J, Rönnelid J, Erlandsson-Harris H, Ulfgren AK, Rantapää-Dahlqvist S, Eklund A, Padyukov L, Alfredsson L. A new model for an etiology of RA; Smoking may trigger HLA-DR (SE) - restricted immune reactions to autoantigens modified by citrullination Arthritis Rheum 2006;54(1):38-46. 
  2. Mullazehi M, Mathsson L, Lampa J, Rönnelid J. Surface-bound immune complexes containing antibodies to collagen type II induce production of TNF-a, IL-1b and IL-8 from peripheral blood mononuclear cells. A potential pathophysiological mechanism for anti-collagen immunity in RA. Arthritis Rheum 2006; 54(6):1759-71. 
  3. Mathsson L, Lampa J, Mullazehi M, Rönnelid J. Immune complexes from RA patients induce Fc(gamma)RII-dependent and rheumatoid factor-correlated TNF-alpha production from peripheral blood mononuclear cells. Arthritis Res Ther 2006; 28(3); R64. 
  4. Elshafie A, EgGhazali G,, Rönnelid J, Venge P. Cystatin C as a marker of immune complex-associated kidney engagement in acute visceral leishmaniasis in Sudan. Am J Trop Med Hyg 2006,75(5):864-868.Unden AL, Andreasson A, Elofsson S, Brismar K, Mathsson L, Ronnelid J, Lekander M. Inflammatory cytokines, behaviour and age as determinants of self-rated health in women. Clin Sci (Lond) 2006;75:864-8. 
  5. Turesson C, Jacobsson LTH, Sturfelt G, Matteson EL, Mathsson L, Rönnelid J. Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis. Ann Rheum Dis 2007;66:59-64. 
  6. Mullazehi M, Mathsson L, Lampa J, Rönnelid J. High anti-collagen type II antibody levels and induction of pro-inflammatory cytokines by anti-collagen antibody containing immune complexes in vitro characterize a distinct RA phenotype associated with acute inflammation at the time of disease onset. Ann Rheum Dis 2007;66:537-41. 
  7. Mathsson L, Åhlin E, Sjövall C, Skogh T, Rönnelid J. Cytokine induction by circulating immune complexes and signs of in-vivo complement activation in systemic lupus erythematosus are associated with the occurrence of anti-SSA antibodies. Clin Exp Immunol 2007;147:513-20. 
  8. Hagforsen E, Hedstrand H, Sunneberg, K, Rönnelid J, Nilsson B, Michaelsson G. Sera from patients with palmoplantar pustulosis show immunoreactivity against endothelial cells both in skin and several internal organs. Acta Derm Venereol 2007;87(3):261-263. 
  9. Elshafie A, Åhlin E, Mathsson L, Elghazali G, Rönnelid J. Immune complex-associated production of granulocyte-macrophage colony-stimulating factor is associated with disease activity and with ongoing sodium stibogluconate therapy in Sudanese patients with visceral leishmaniasis. Journal of Immunology 2007;178(8);5383-9. 
  10. Sigurdsson S, Padyukov L, Kurreeman FAS, Liljedahl U, Wiman A-C, Alfredsson L, Rönnelid J, Klareskog L, Huizinga TWJ, Alm G, Syvänen A-C, Rönnblom L. Association of a haplytype in the promoter region of the interferon regulatory factor 5 gene with rheumatoid arthritis. Arthritis Rheum 2007;56(7):2202-2210. 
  11. Källberg H, Padyukov L, Plenge RM, Rönnelid J, Gregersen PK, van der Helm-van Mil, Toes REM, Huizinga TW, Klareskog L, Alfredsson L. Gene-gene and gene-environment interactions involving HLA-DR, PTPN22 and smoking in two subsets of rheumatoid arthritis. Am J Hum Genet 2007;80(5):867-875. 
  12. Mathsson L, Mullazehi M, Wick MC, Sjöberg O, van Vollenhoven R, Klareskog L, Rönnelid J. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiological progression as compared to antibodies against cyclic citrullinated peptide (anti-CCP). Arthritis Rheum 2008; 58(1):36-45). 
  13. Guo JP, Bäckdahl L, Marta M, Mathsson L, Rönnelid J, Lorentzen JC. Profound and Paradoxical Impact on Arthritis and Autoimmunity of the Antigen Presenting Lectin-like Receptor Complex (APLEC). Arthritis Rheum (2008;58(5):1343-53. 
  14. Raza K, Mullazehi M, Salmon M, Buckley CD, Rönnelid J. Anti-collagen type II antibodies in patients with very early synovitis. Ann Rheum Dis 2008;67:1354-1355. 
  15. Lundström E, Källberg H, Smonikova M, Ding B, Rönnelid J, Alfredsson L, Klareskog L, Padyukov L. Opposing effects of HLA-DRB1*13 alleles on the risk of developing ACPA-positive and ACPA-negative Rheumatoid Arthritis. Arthritis Rheum 2009;60(4):924-30. 
  16. Barbasso Helmers S, Englund P, Åhlin E, Heimbürger M, Fathi M, Rönnelid J, Lundberg IE. Anti-Jo-! positive sera from polymyositis patients with interstitial lund disease induce ICAM-1 expression in human lung endothelial cells. Arthritis Rheum 2009;60(8):2524-30. 
  17. Eloranta ML, Lövgren T, Finke D, Mathsson L, Rönnelid J, Kastner B, Alm GV, Rönnblom L. Regulation of interferon-alpha production induced by RNA-containing immune complexes in plasmacytoid dendritic cells. Arthritis Rheum 2009;60(8):2418-27. 
  18. Wenink MH, Santegoets KC, Roelofs MF, Huijbens R, Koenen HJ, van Beek R, Joosten I, Meyer-Wentrup F, Mathsson L, Ronnelid J, Adema GJ, Bonvini E, Koenig S, van den Berg WB, van Riel PL, Radstake TR. The inhibitory Fc{gamma}IIb receptor dampens TLR4-mediated immune responses and is selectively up-regulated on dendritic dells from rheumatoid arthritis patients with quiescent disease. J. Immunol 2009;183(7);4509-20. 
  19. Madhi H, Fisher B, Källberg H, Plant D, Malmström V, Rönnelid J, Charles P, Ding B, Alfredsson L, Padyukov L, Symmons DPM, Venables P, Klareskog L, Lundberg K. Specific interaction between genotype, smoking and autoimmunity to citrullinated alpha-enolase in the etiology of rheumatoid arthritis. Nat Genet. 2009 Dec;41(12):1319-24.
  20. Raza K, Mathsson L, Buckley CD, Filer A, Rönnelid J. Anti-modified citrullinated vimentin (MCV) antibodies in patients with very early synovitis. Ann Rheum Dis 2010;69(3):627-8. 
  21. Rönnelid J, Barbasso-Helmers S, Storfors H, Grip K, Rönnblom L, Franck-Larsson K, Nordmark G, Lundberg IE. Use of a commercial line blot assay as a screening test for autoantibodies in inflammatory myophathies. Autoimmun Rev. 2009;9(1):58-61. 
  22. Stolt P, Källberg H, Rönnelid J, Lundberg I, Klareskog L, Alfredsson L. Silica exposure is associated with increased risk of developing Rheumatoid Arthritis defined by the presence of antibodies to citrullinated peptides. Ann Rheum Dis. 2010;69(6):1072-6. 
  23. Hansson H, Rönnelid J. Detection of antinuclear antibodies by the Inno-Lia ANA Update test in canine systemic rheumatic disease. Veterinary Clinical Pathology, 2010;39(2):215-20.
  24. Ahren-Moonga J, Lekander M, von Blixen N, Rönnelid J, Holmgren S, af Klinteberg B. Levels of tumour necrosis factor-alpha and interleukin-6 in severely ill patients with eating disorders. Neuropsychobiology, 2011;63(1):8-14. 
  25. Payukov L, Seielstad M, Ong RTH, Ding B, Rönnelid J, Seddighzadeh M, Alfredsson L, Klareskog L. Genome-wide study identifies distinct associations in ACPA positive vs. ACPA negative rheumatoid arthritis. Ann Rheum Dis 2011; 70(2):259-265. 
  26. Nader GA, Dastmalchi M, Alexanderson H, Grundtman C, Germapudi R, Esbjörnsson M, Wang Z, Rönnelid J, Hoffman EP, Nagaraju K, Lundberg IE. A longitudinal, integrated clinical, histological and mRNA profiling study of resistance exercise in myositis. Mol Med 2010;16(11-12):455-64. 
  27. Nyhäll-Wåhlin BM, Turesson C, Jacobson L, Nilsson JÅ, Forslind K, Albertsson K, Rönnelid J, Petersson IF. The presence of rheumatoid nodules at early rheumatoid arthritis diagnosis predicts radiographic progression of joint destruction over five years. Scand J Reumatol 2011;40(2):81-7. 
  28. Ahlgren KM, Moretti S, Ardesjö Lundgren B, Karlsson I, Åhlin E, Norling A, Hallgren Å, Perheentupa J, Gustafsson J, Rorsman F, Crewther PE, Rönnelid J, Bensing S, Scott HS, Kämpe O, Romani L, Lobell A. Increased IL-17A Secretion in Response to Candida albicans in Autoimmune Polyendocrine Syndrome Type 1 and its Animal Model. Eur J Immunol 2011;41(1):235-45. 
  29. Källberg H, Ding B, Padyukov L Bengtsson C, Rönnelid J, Klareskog L, Alfredsson L. Smoking is a major preventable risk factor for RA; Estimations of risk for ACPA-positive RA after various exposures to cigarette smoke. Ann Rheum Dis 2011;70(3):508-11. 
  30. Elshafie A, Åhlin E, Douhan Håkansson L, ElGhazali G, Hassan El Safi S, Rönnelid J, Venge P. Activity and turnover of eosinophil and neutrophil granulocytes are increased in visceral leishmaniasis. Int J Parasitol, 2011;41(3-4):463-9. 
  31. Kokkonen H, Mullazehi M, Berglin E, Hallmans G, Wadell G, Rönnelid J, Rantapää-Dahlqvist S. Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis. Arthritis Res Ther 2011;13(1):R13. 
  32. Fischer B, Plant D, Brode M, van Vollenhoven R, Mathsson L, Symmons D, Lundberg K, Rönnelid J*, Venables P* Antibodies to citrullinated alpha-enolase peptide 1 and clinical and radiological outcomes in rheumatoid arthritis. Ann Rheum Dis 2011;70(6):1095-8. * joint shared last authorship. 
  33. Ärlestig L, Mullazehi M, Rocklöv J, Rönnelid J, Rantapää-Dahlqvist S. Antibodies against cyclic citrullinated peptides of IgG, IgA and IgM isotype and rheumatoid factor of IgM and IgA isotype are increased in unaffected members of multicase rheumatoid arthritis families from Northern Sweden. Ann Rheum Dis 2012;71(6):825-9. 
  34. Gunnarsson I, Rönnelid J. No occurrence of M-type PLA2 receptor antibodies in active membranous lupus nephritis. Am J Kidney Dis. 2012 Apr;59(4):585-6. 
  35. Laki J, Lundström E, Snir O, Rönnelid J, Ganji I, Catrina AI, Bengtsson C, Saevarsdottir S, Wick MC, Alfredsson L, Klareskog L, Padyukov L. Very high level of anti-citrullinated peptide antibodies associate with HLA-DRB1*15 Non-Shared Epitope Allele in patients with rheumatoid arthritis. Arthritis Rheum. 2012 Jul;64(7):2078-84.
  36. Åhlin E, Mathsson L, Eloranta ML, Jonsdottir T, Gunnarsson I, Rönnblom L, Rönnelid J.Autoantibodies associated with RNA are more enriched than anti-dsDNA antibodies in circulating immune complexes in SLE. Lupus. 2012 May;21(6):586-95. 
  37. Gerlag DM, Raza K, van Baarsen LG, Brouwer E, Buckley CD, Burmester GR, Gabay C, Catrina AI, Cope AP, Cornelis F, Dahlqvist SR, Emery P, Eyre S, Finckh A, Gay S, Hazes JM, van der Helm-van Mil A, Huizinga TW, Klareskog L, Kvien TK, Lewis C, Machold KP, Rönnelid J, Schaardenburg DV, Schett G, Smolen JS, Thomas S, Worthington J, Tak PP. EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Ann Rheum Dis. 2012 May;71(5):638-41. 
  38. Mullazehi M, Wick MC, Klareskog L, von Vollenhoven R, Rönnelid J. Anti-type II collagen antibodies are associated with early radiographic destruction in rheumatoid arthritis. Arthritis Res Ther. 2012 May 1;14(3):R100. 
  39. Hansson M, Mathsson L, Schlederer T, Israelsson L, Matsson P, Nogueira L, Jakobsson PJ, Lundberg K, Malmström V, Serre G, Holmdahl R, Nystrand R, Klareskog L, Rönnelid J. Validation of a multiplex chip-based for the detection of autoantibodies against citrullinated peptides. Athritis Res Ther, 2012;14:R201. 
  40. Brink M, Hansson M, Mathsson L, Jakobsson PJ, Holmdahl R, Hallmans G, Stenlund H, Rönnelid J, Klareskog L, Rantapää-Dahlqvist S. Multiplex analyses of antibodies against citrullinated peptides in individuals prior to development of rheumatoid arthritis. Arthritis Rheum 2013 Apr;65(4):899-910. 
  41. Turesson C, Mathsson L, Jacobsson LTH, Sturfelt G, Rönnelid J. Antibodies to modified citrullinated vimentin are associated with severe extra-articular manifestations in rheumatoid arthritis. Ann Rheum Dis, in press (2013).

Reviews, bokkapitel:

  1. Klareskog L, Padyukov L, Rönnelid J, Alfredsson L. Genes, environment and immunity in the development of rheumatoid arthritis. Curr Opin Immunol 2006;18:1-6. 
  2. Rönnelid J. Kollagenantikroppar och akut insjuknande i reumatoid artrit. Läkartidingen 2007;104 (34):2317. 
  3. Rönnelid J, Mullazehi M, Mathsson L. Differential prognostic impact of autoantibodies and inflammation markers in early rheumatoid arthritis. Autoantigens, Autoantibodies, autoimmunity, Report from the 8th Dresden symposium on autoantibodies volume 5. 
  4. Klareskog L, Rönnelid J, Lundberg K, Padyukov L, Alfredsson L. Immunity to Citrullinated Proteins in Rheumatoid Arthritis. Annu Rev Immunol 2008;26:651-75. 
  5. Klareskog L, Widhe M, Hermansson M, Rönnelid J. Antibodies to citrullinated proteins in arthritis; pathology and promise. Curr Opin Rheumatol 2008 May;20(3):300-5. 
  6. Klareskog L, Rönnelid J, Alfredsson L. Environmental risk factors for rheumatoid arthritis. Book chapter in: Rheumatology, Eds. Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH. Mosby/Elsevier 2008. (p. 28-34) ISBN 978-0-323-05475-1. 
  7. Rönnelid J. Mölne Johan, Wold Agnes: Inflammation. Läkartidningen 2008;20:1512 (book review). 
  8. Rönnelid J, Åhlin E, Nilsson B, Nilsson-Ekdahl K, Mathsson L. Immune complex-mediated cytokine production is regulated by classical complement activation both in vivo and in vitro. Adv Exp Med Biol 2008;632:187-201. 
  9. Olcén P, Åberg AK, Fredlund H, Rönnelid J, Aspevall O, Truedsson L. Hur kvalitetssäkrar vi den patientnära diagnostiken (mikrobiologi/immunologi)? Läkartidningen 2008;48:3559-60. 
  10. Dahle C, Skogh T, Rönnelid J. Kapitel 13. Autoantikroppar. Klinisk immunologi. Studentlitteratur 2012. ISBN 978-91-44-07426-9.